Pricing Log in Create free account
Friday 6 November 2026 Export MEDP’s income statement to Excel — free account

Medpace Holdings, Inc.

MEDP Healthcare Diagnostics & Research

Medpace Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.5 billion, up 20.0% from fiscal 2024.

Revenue
+8.50%
EPS
+24.6%
Free cash flow
−16.6%

Quarter to September 2026, against a year earlier

656.11 21.13 +3.33%
Market cap
$17.8B
P/E
34.6×
Fwd P/E
35.8×
Dividend yield
—
F-score
8/9
Altman Z
8.04
Beneish M
−2.92
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Medpace Holdings, Inc. 10-Q filed Oct 22, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed · accepted 4:02 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors
Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Jul 23, 2026: 1 added · 13 modified; 13 with only figures updated

  1. Modified · Nine Months Ended September 30, 2026 compared to Nine Months Ended September 30, 2025

    Total revenue increased by $104.056.1 million, to $707.3716.0 million for the three months ended JuneSeptember 30, 2026, from $603.3659.9 million for the three months ended JuneSeptember 30, 2025. Total revenue increased by $252.1308.2 million, to $1,413.92,129.9 million for the sixnine months ended JuneSeptember 30, 2026, from $1,161.91,821.8 million for the sixnine months ended JuneSeptember 30, 2025. The increase for the three and sixnine months ended JuneSeptember 30, 2026 was primarily driven by growth within the Metabolic, Oncology, and Central Nervous System and AVAI therapeutic areas, compared to the same periods in the prior year.

13 more changes in this Item, word by word, in Powerpack.